Marini, Joseph C.
Sendecki, Jocelyn
Cornillie, Freddy
Popp, John W. Jr.
Black, Shawn
Blank, Marion
Gils, Ann
Van Stappen, Thomas
Hamann, Dörte
Rispens, Theo
Thérien, Lina
Chun, Kelly
Shankar, Gopi
Article History
Received: 3 May 2016
Accepted: 25 August 2016
First Online: 6 September 2016
Compliance with Ethical Standards
:
: Authors’ declaration of personal interests: T. Van Stappen is a PhD fellow of the Agency for the Promotion and Innovation by Science and Technology in Flanders (IWT, Flanders). A. Gils received lecture fee(s) from MSD, Pfizer, AbbVie, and Janssen Biologicals; consultant fees from UCB and institution licensed the infliximab ELISA to apDia. F. Cornillie is a former employee of Janssen Biologics, BV and is a current employee of MSD International. K. Chun is an employee of LabCorp. L. Thérien was an employee of Dynacare at the time the study was conducted. D. Hamann is an employee of Sanquin. T. Rispens is an employee of Sanquin and has received lecture fees from Pfizer and AbbVie. J. Marini, J. Sendecki, and G. Shankar are employees of Janssen Research & Development, LLC. S. Black and M. Blank are employees of Janssen Scientific Affairs, LLC.This study was funded by Janssen Scientific Affairs, LLC (Horsham, PA). This study was designed and conducted by KU Leuven, LabCorp, Dynacare, Sanquin, Janssen Scientific Affairs, LLC, and Janssen Research & Development, LLC who jointly analyzed and interpreted the data, and contributed to the manuscript.